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Abstract 22 
Background/Objectives: The effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on plasma concentrations of 23 
adiponectin, a fat-derived hormone with anti-atherogenic and anti-inflammatory properties, is uncertain. A systematic 24 
review and meta-analysis of randomized controlled trials (RCTs) was conducted to investigate this association in 25 
humans. 26 
Methods: RCTs investigating the impact of DPP-4 inhibitors on plasma adiponectin concentrations were identified after 27 
searching PubMed-Medline, SCOPUS, and Google Scholar databases (up to February 2015). As quantitative data 28 
synthesis methods, the random-effects model and the generic inverse variance method were applied. Standard methods 29 
of meta-regression, sensitivity analysis, and publication bias assessments were performed. 30 
Results: Eight RCTs with nine treatment-arms were included. Meta-analysis did not suggest a significant pooled effect 31 
of DDP-4 inhibitors on adiponectin values (weighed-mean-difference [WMD]: 0.19 µg/mL, 95%CI: -0.50, 0.88). 32 
However, a significant elevation of plasma adiponectin concentrations was observed in the subset of trials with 33 
vildagliptin (WMD: 0.55 µg/mL, 95%CI: 0.13, 0.98, p=0.010) but not sitagliptin (WMD: -0.06 µg/mL, 95%CI: -1.13, 34 
1.00, p=0.907). There was a significant elevation of plasma adiponectin levels in the subset of trials comparing DPP-4 35 
inhibitors versus placebo or no treatment (WMD: 0.74 µg/mL, 95%CI: 0.36, 1.12, p <0.001) but not in the subset using 36 
hypoglycemic drugs as comparators), or using other hypoglycemic drugs (WMD: -0.18 µg/mL, 95%CI: -0.99, 0.62, 37 
p=0.654). No significant effect was found for treatment duration, confirmed by meta-regression analyses.  38 
Conclusions: DPP-4 inhibitors cause a significant increase in plasma adiponectin concentrations and this effect is 39 
greater with vildagliptin than sitagliptin. 40 
 41 
 42 
Keywords: Adiponectin; Cardiovascular diseases; Dipeptidyl peptidase-4 inhibitors; Meta-analysis; Systematic review; 43 
Type 2 diabetes mellitus. 44 
45 
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1. Introduction 46 
Incretins are gastrointestinal hormones released in response to food intake to increase insulin secretion [1]. Glucagon-47 
like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are the two gut peptides accounting for 48 
most of the incretin effects; both stimulate in a glucose-dependent manner the secretion of insulin, delay gastric 49 
emptying, increase satiety, decrease adipogenesis, and enhance adipokine expression [1-3]. GLP-1 inhibits the secretion 50 
of glucagon by α-cells, thus reducing hepatic glucose production [1]. The enzyme dipeptidyl peptidase-4 (DPP-4) is 51 
responsible for the rapid proteolytic cleavage of GLP-1 and GIP to inactive metabolites [4]. DPP-4 inhibitors are a new 52 
drug class that delay endogenous degradation of GLP-1 and GIP and produce approximately a 2-fold increase in the 53 
concentrations of these gut peptides [1,5-6]. Currently available DPP-4 inhibitors include sitagliptin, vildagliptin, 54 
saxagliptin, teneligliptin, anagliptin, dutogliptin, alogliptin, and linagliptin. Among these, sitagliptin and vildagliptin are 55 
the most frequently used. 56 
A large body of literature has shown that DDP-4 inhibitors exert beneficial effects in type 2 diabetes by improving β-57 
cell function, ameliorating both fasting and postprandial glucose values, reducing insulin resistance, decreasing body 58 
weight, inflammatory markers, oxidative stress and LDL-cholesterol, and increasing HDL-cholesterol and vascular 59 
endothelial function [7-15]. Therefore, cardioprotective effects have been proposed for this class of drugs [3,5,16-19], 60 
however, findings from  large trials and recent meta-analyses have not supported cardiovascular (CV) benefits for DDP-61 
4 inhibitors [20-22]. 62 
Among the supposed CV benefits of these drugs, many glucose-independent effects are included, such as the increased 63 
circulating levels of incretins and activity of B-type natriuretic peptide, neuropeptide Y, stromal cell-derived factor 1-64 
alpha, and the effects on endothelial function and adipokine concentrations [12,17,23-25]. Adiponectin is a fat-derived 65 
hormone with anti-atherogenic and anti-inflammatory properties; its concentrations decrease in obesity and are 66 
inversely associated with visceral fat mass, insulin resistance, glucose intolerance, dyslipidemia, chronic subclinical 67 
inflammation and oxidative stress [26-27]. Furthermore, decreased levels of adiponectin have been related with an 68 
increased risk of CV diseases and vascular injury, while increased values are associated with lower risk of myocardial 69 
infarction and significantly predicted a lower risk of future CV events in men [28-29]. 70 
 71 
The effects of DDP-4 inhibitors on circulating adiponectin levels are highly uncertain, since either an increase [9-10,13-72 
14,24-25] or no effects [8,15,26,30] have been reported. 73 
 74 
The aim of this study was to conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) in 75 
order to investigate the effect of the treatment with DPP-4 inhibitors on the plasma concentrations of adiponectin in 76 
humans. 77 
 78 
2. Methods 79 
2.1 Search Strategy 80 
A similar research approach has been used and described in previous original articles [31-34]. Briefly, this study was 81 
designed according to the guidelines of the 2009 preferred reporting items for systematic reviews and meta-analysis 82 
(PRISMA) statement [35], SCOPUS (http://www.scopus.com), Medline (http://www.ncbi.nlm.nih.gov/pubmed) and 83 
Google Scholar (http://www.scholar.google.com) databases were searched using the following search terms in titles and 84 
abstracts (also in combination with MESH terms): (“dipeptidyl peptidase 4” OR “dipeptidyl peptidase IV” OR DPP-4 85 
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OR DPP-IV OR sitagliptin OR saxagliptin OR vildagliptin OR linagliptin OR dutogliptin OR alogliptin OR 86 
teneligliptin OR anagliptin) AND (adiponectin). The wild-card term ‘‘*’’ was used to increase the sensitivity of the 87 
search strategy. No language restriction was used in the literature search. The search was limited to studies in humans. 88 
The literature was searched from inception to February 21, 2015. 89 
 90 
2.2 Study Selection 91 
Original studies meeting the following inclusion criteria were selected: (i) randomized controlled clinical trials with 92 
either parallel or cross-over design, (ii) investigating the impact of DPP-4 inhibitors, either as monotherapy or 93 
combination therapy, on plasma/serum concentrations of adiponectin, (iii) treatment duration of at least two weeks, (iv) 94 
providing sufficient information on adiponectin concentrations at baseline and end of trial in both treatment and control 95 
groups or the net change values. Exclusion criteria were (i) lack of a control group in the study design, (ii) observational 96 
studies with case-control, cross-sectional or cohort design, and (iii) lack of sufficient information on baseline or end of 97 
trial adiponectin concentrations. 98 
 99 
2.3 Data extraction  100 
After reviewing eligible studies, the following data were abstracted: 1) first author's name; 2) publication date; 3) study 101 
location; 4) study design; 5) number of participants in the DPP-4 and control groups; 5) dose and duration of treatment 102 
in the treatment group; 6) drugs used in the control group; 7) age, gender, and body mass index (BMI) of study 103 
participants; 8) prevalence of coronary heart disease and hypertension; and 9) baseline and end of trial plasma 104 
concentrations of adiponectin. 105 
 106 
2.4 Quality assessment 107 
A systematic assessment of bias in the included studies was performed using the following Cochrane criteria [36]: 108 
adequacy of sequence generation, allocation concealment, blinding, addressing of dropouts (incomplete outcome data), 109 
selective outcome reporting, and other potential sources of bias. Based on the Cochrane Handbook recommendations, a 110 
judgment of “yes” indicated low risk of bias, while “no” indicated high risk of bias. Labeling an item as “unclear” 111 
indicated an unclear or unknown risk of bias. 112 
 113 
2.5 Quantitative Data Synthesis 114 
Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) V2 software (Biostat, NJ) [37]. Net changes 115 
in measurements (change scores) were calculated as follows: measure at end of follow-up − measure at baseline. For 116 
cross-over trials, net change in plasma concentrations of adiponectin were calculated by subtracting the value after 117 
control intervention from that reported after treatment. All values were calculated in percentage changes from baseline 118 
levels. Standard deviations (SDs) of the mean difference were calculated using the following formula: SD = square root 119 
[(SDpre-treatment)2 + (SDpost-treatment)2 – (2R × SDpre-treatment × SDpost-treatment)], assuming a correlation coefficient (R) = 0.5. If 120 
the outcome measures were reported in median and inter-quartile range, mean and standard SD values were estimated 121 
using the method described by Hozo et al. [38]. When standard error of the mean (SEM) was only reported, standard 122 
deviation (SD) was estimated using the following formula: SD = SEM × sqrt (n), where n is the number of subjects. 123 
When the results were presented in multiple time points, only data relating to the longest duration of treatment were 124 
considered. 125 
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In order to compensate for the heterogeneity of studies in terms of demographic characteristics of the included 126 
populations and also differences in study design, the random-effects model (using Der Simonian-Laird method) and the 127 
generic inverse variance method were applied. Heterogeneity was quantitatively assessed using I2 index. Effect sizes 128 
were expressed as weighted mean difference (WMD) and 95% confidence interval (CI). In order to evaluate the 129 
influence of each study on the overall effect size, sensitivity analysis was conducted using leave-one-out method, i.e. 130 
removing one study each time and repeating the analysis [39-40]. 131 
 132 
2.6 Meta-regression 133 
Random-effects meta-regression was performed using unrestricted maximum likelihood method to evaluate the 134 
association between calculated WMD and potential moderators including duration of treatment with DPP-4 inhibitors. 135 
 136 
2.7 Publication bias 137 
Potential publication bias was explored using visual inspection of Begg’s funnel plot asymmetry, fail-safe N test, and 138 
Begg’s rank correlation and Egger’s weighted regression tests. Duval & Tweedie “trim and fill” method was used to 139 
adjust the analysis for the effects of publication bias [41]. 140 
 141 
3. Results 142 
3.1 Flow and characteristics of included studies 143 
With the initial literature search, 189 articles were found (Figure 1). All these records were screened, and 132 did not 144 
meet the inclusion criteria. The full text of the remaining 11 studies was carefully assessed for eligibility and 8 were 145 
selected for the meta-analysis because they satisfied the inclusion criteria. Reasons for rejecting the other 3 articles 146 
were: lack of comparison group, short treatment duration (< 2 weeks). A total number of 810 subjects were included in 147 
the 8 eligible studies, comprising 423 individuals treated with DPP-4 inhibitors alone [15,30] or in combination with 148 
metformin [9-10,13-14], pioglitazone [8], biguanides/sulfonylureas [25], miglitol [30], and 387 individuals treated with 149 
placebo or other oral hypoglycemic drugs (Table 1). Overall, we have evaluated 8 eligible studies with 9 treatment 150 
arms. The largest study had a population size of 178 subjects [10], while the smallest study recruited only 26 subjects 151 
[25]. Included studies were published between 2010-2014 and were conducted in Italy [8-10,14], Japan [15,25,30], and 152 
Germany [13]. The following DPP-4 inhibitors were used: sitagliptin [8,10,15,25,30] and vildagliptin [9,13-14]. The 153 
duration of DPP-4 inhibitors therapy was variable, ranging from 3 months [25] to 12 months [8-10,15]. All these 154 
randomized trials had a parallel design; only two were placebo-controlled [9-10], the others compared DPP-4 inhibitors 155 
with other oral hypoglycemic drugs [8,13-15,25,30]. The inclusion criteria were quite homogeneous: most patients were 156 
affected by poorly controlled type 2 diabetes [8-10,14,25]. The demographic and baseline biochemical parameters of 157 
the included studies are shown in Table 1. 158 
 159 
3.2 Risk of bias assessment 160 
Some of the analyzed studies provided insufficient information about randomization procedures (Table 2). Similarly, 161 
blinding of participants or researchers was often inadequate or absent [13,15,25,30]. Furthermore, most study designs 162 
did not include a placebo arm [8,13-15,25,30] and two studies had baseline imbalance in the patient characteristics 163 
[25,30]. However, all studies appeared to be free of selective outcome reporting.      164 
 165 
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3.3 Effect of DPP-4 inhibitors on plasma adiponectin concentrations 166 
Meta-analysis did not suggest a significant pooled effect (WMD: 0.19 µg/mL, 95% CI: -0.50, 0.88, p= 0.597). 167 
However, this result was sensitive to one study [8]. After excluding the referred trial from the analysis, a significant 168 
increase in plasma adiponectin levels was found (WMD: 0.58 µg/mL, 95% CI: 0.27, 0.89, p< 0.001) (Figure 2). When 169 
the studies were categorized according to the type of DPP-4 inhibitor used, there was a significant elevation of plasma 170 
adiponectin levels in the subset of trials with vildagliptin (WMD: 0.55 µg/mL, 95% CI: 0.13, 0.98, p= 0.010) but not 171 
sitagliptin (WMD: -0.06 µg/mL, 95% CI: -1.13, 1.00, p= 0.907) (Figure 3 A and B). With respect to treatment duration, 172 
there was no significant treatment effect in either subgroup of trials lasting < 48 (WMD: 0.27 µg/mL, 95% CI: -0.26, 173 
0.81, p= 0.313) or ≥ 48 weeks (WMD: 0.16 µg/mL, 95% CI: -1.06, 1.38, p= 0.802) (Figure 3 C and D). Finally, there 174 
was a significantly greater effect of DPP-4 inhibitors on plasma adiponectin concentrations when compared against 175 
placebo (or no treatment) (WMD: 0.74 µg/mL, 95% CI: 0.36, 1.12, p< 0.001) rather than active control (WMD: -0.18 176 
µg/mL, 95% CI: -0.99, 0.62, p= 0.654) (Figure 3 E and F). 177 
 178 
3.4 Meta-regression 179 
Random-effects meta-regression was performed to assess if the adiponectin response to DPP-4 inhibitors is associated 180 
with duration of treatment. The results did not suggest any significant association between the changes in plasma 181 
concentrations of adiponectin and duration of treatment (slope: -0.003; 95% CI: -0.04, 0.04; p = 0.883) (Figure 4).  182 
 183 
3.5 Publication bias 184 
The funnel plot of the study standard error by effect size (WMD) was slightly asymmetric, suggesting potential 185 
publication bias in the meta-analysis (Figure 5). Using “trim and fill” correction, one potentially missing RCT was 186 
imputed on the left side of funnel plot, yielding an effect size of 0.06 (95% CI: -0.56, 0.67). Egger’s linear regression 187 
(intercept = 0.58, standard error = 1.29; 95% CI = -2.49, 3.64, t = 0.45, df = 7, two-tailed p = 0.670) and Begg’s rank 188 
correlation tests (Kendall’s Tau with continuity correction = -0.31, z = 1.15, two-tailed p-value = 0.251) did not suggest 189 
any potential publication bias. 190 
 191 
4. Discussion 192 
Findings from the current meta-analysis of randomized controlled trials suggested that treatment with DPP-4 inhibitors 193 
was associated with a modest increase in plasma adiponectin levels in patients with type 2 diabetes. This effect was 194 
evident for vildagliptin but not sitagliptin, and also in trials comparing DPP-4 inhibitors versus placebo but not other 195 
hypoglycemic drugs. The duration of treatment did not affect the results. 196 
In most [24,42-45], but not all [46-47] experimental animal models, treatment with DPP-4 inhibitors has been shown to 
197 
increase plasma adiponectin concentrations. Similarly, most open-label human studies [12,48-49] but not all [11,50] 
198 
have suggested an improvement in vascular endothelial function and circulating adiponectin levels after the use of 
199 
DDP-4 inhibitors.  
200 
Many potential mechanisms have been hypothesized to explain this effect. There is evidence indicating that treatment 201 
with DPP-4 inhibitors improves weight loss and decreases inflammation and oxidative stress in type 2 diabetic patients 202 
[11]. Nevertheless, the increase in adiponectin concentrations after therapy with DPP-4 inhibitors has been reported 203 
without change in body weight [13,25], and DPP-4 inhibitors do not usually promote weight loss [1]. In rats, DDP-4 204 
inhibitors were found to increase the mRNA expression of adiponectin receptor 1, the receptor of adiponectin more 205 
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abundantly expressed in muscles [45]. DPP-4 is considered as a new adipokine released by fully differentiated 206 
adipocytes, above all by visceral fat, and its levels are inversely correlated with adiponectin concentrations [51]. 207 
Therefore, inhibiting DDP-4 by DPP-4 inhibitors may potentially increase adiponectin levels. Furthermore, adiponectin 208 
levels are inversely associated with insulin resistance [28], and the insulin sensitizing effects of the DPP-4 inhibitors 209 
[42], as well as other pharmacologic and non-pharmacologic insulin sensitizing approaches [52-53], might beneficially 210 
impact on adiponectin concentrations. Reduction of oxidative stress by DPP-4 inhibitors [11,25] is another possible 211 
mechanism, since increase in systemic and/or local oxidative stress reduce adiponectin production [25]. Finally, the 212 
effects of DPP-4 inhibitors on adiponectin values could be mediated by the increased concentrations of GLP-1. 213 
Exendin-4, a GLP-1 receptor agonist, has been shown to promote adiponectin secretion by increasing adiponectin 214 
mRNA expression in high fat-fed rats and, via the protein kinase-A pathway, in 3T3-L1 adipocytes [54-55]. 215 
DPP-4 inhibitors have been reported to improve vascular endothelial dysfunction, a marker of the very early stage of 216 
atherosclerosis, both in experimental and human studies. In animals, these drugs enhance nitric oxide (NO) 217 
bioavailability [56-57], attenuate intimal hyperplasia in response to vascular injury, reduce atherosclerotic lesions 218 
[44,58-59], and augment neovascularization by increasing circulating endothelial progenitor cells [60]. In humans, 219 
DPP-4 inhibitors stimulate ischemia-induced revascularization through endothelial NO synthase (eNOS) signaling [24], 220 
and reverse vascular endothelial dysfunction by increasing flow-mediated dilatation [12,48,61]. In many of these 221 
studies, the increase in adiponectin concentrations is the relevant factor responsible for the protective action of DPP-4 222 
inhibitors on endothelial dysfunction [12,24,44,48]. Adiponectin stimulates NO production by eNOS, plays anti-223 
inflammatory roles, and favorably impacts on lipid and glucose metabolism. Consistent with all these effects, 224 
hypoadiponectinemia has been proposed as a risk factor for the development of cardiovascular diseases [26-29,62]. 225 
Therefore, increased adiponectin levels might be one of the mechanisms of the pleiotropic effects of DPP-4 inhibitors. 226 
Other beneficial effects include reduction of glucose values, insulin resistance, oxidative stress, LDL-cholesterol, and 227 
increase of HDL-cholesterol and vascular endothelial function [7-15]. Furthermore, DPP-4 inhibitors exert strong anti-228 
inflammatory actions both in animals and in humans, by decreasing the activity and concentrations of interleukin-1ß, 229 
interleukin-6, tumor necrosis factor-α, C-reactive protein, and by the inhibition of T cell migration [14,46,55,63-68]. 230 
Cardio-protective benefits have therefore been proposed for this class of drugs. 231 
Human studies in type 2 diabetic patients treated with DPP-4 inhibitors have reported decreased atherosclerosis 232 
progression [69], mitigation of myocardial dysfunction during dobutamine stress echocardiography [70-71], while the 233 
administration of stromal cell-derived factor 1-alpha, whose biological activity is augmented by DPP-4 inhibitors, 234 
resulted in clinical improvements in patients with ischemic cardiomyopathy [72]. These results have been confirmed in 235 
many experimental and animal studies, and human long-term CV outcome trials in patients with type 2 diabetes are 236 
ongoing [4-5,16-17,19,23]. 237 
In contrast to the favorable results observed in experimental and short-term clinical studies, data from longer clinical 238 
trials are, however, disappointing, since two large RCTs in patients with type 2 diabetes and CV diseases or at high risk 239 
of adverse CV events showed that DPP-4 inhibitors neither increased nor decreased CV outcomes [20-21]; furthermore, 240 
the rate of hospitalization for heart failure was increased with saxagliptin [20]. Therefore, the CV efficacy of DPP-4 241 
inhibitor isn’t yet fully known and warrants further investigation. 242 
 243 
Our subgroup analysis revealed a significant elevation of plasma adiponectin levels in the subset of trials with 244 
vildagliptin, but not sitagliptin, suggesting a specific effect rather than a class effect of DPP-4 inhibitors. The 245 
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pharmacodynamic profile of all DPP-4 inhibitors is similar across the drug class, with minor pharmacokinetic 246 
differences [6,18,22]. However, reduced daily glucose fluctuations have been reported with vildagliptin compared with 247 
sitagliptin [11,73], and this led to a greater increase in GLP-1 and β-cell response, and reduction of plasma levels of 248 
glucagon, nitrotyrosine, and inflammatory markers [11]. Differences in the binding properties of these drugs (sitagliptin 249 
binds non-covalently to the enzyme, while vildaglitin forms a covalent adduct, with a stable and longer inhibition), and 250 
a hypothesized better bioavailability might justify the differential effects of these two DPP-4 inhibitors on plasma 251 
adiponectin levels [11]. Indeed, a significant benefit of vildagliptin, but not of other DPP-4 inhibitors, has been found in 252 
the reduction of stroke risk [22], and intima-media thickness [69]. Longer follow-up studies, comparing the effects of 253 
specific DPP-4 inhibitors are needed to better characterize the effects of these drugs on the risk of CV endpoints; 254 
adiponectin concentrations should be evaluated too, since this adipokine might play a role on the differential CV 255 
benefits of the DPP-4 inhibitors.  256 
 257 
4.1 Limitations 258 
The present meta-analysis has potential limitations that should be mentioned. The included studies were heterogeneous, 259 
generally short-term (≤6 months), and with small population sizes. Only two types of DPP-4 inhibitors were assessed in 260 
the included trials, thus the impact of other members of this drug class on adiponectin status remains elusive. 261 
Furthermore, most of included studies were not primarily designed to assess the effects of DPP-4 inhibitors on 262 
adiponectin concentrations. Finally, the number of trials that were included was relatively few, which made it difficult 263 
to assess any dose-response relationship. 264 
 265 
4.3 Conclusions 266 
Findings from the present meta-analysis of RCTs showed a significant increase in the values of plasma adiponectin 267 
concentrations following treatment with vildagliptin, thus suggesting another aspect of the pleiotropic properties of 268 
DPP-4 inhibitors. While waiting the results from ongoing long-term trials on CV outcomes, this meta-analysis adds a 269 
small piece of evidence to the existing knowledge about the efficacy of DDP-4 inhibitors in type 2 diabetic patients. 270 
 271 
Abbreviations 272 
CI= confidence interval, CMA= Comprehensive Meta-Analysis, CV= cardiovascular, DPP-4= dipeptidyl peptidase-4, 273 
GIP= glucose-dependent insulinotropic polypeptide, GLP-1= Glucagon-like peptide-1, SD= standard deviation, RCTs= 274 
randomized controlled trials, SEM= standard error of the mean, WMD= weighted mean difference. 275 
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Figure captions 493 
 494 
Figure 1. Flow chart of the number of studies identified and included into the meta-analysis.   495 
Figure 2. Forest plot displaying weighted mean difference and 95% confidence intervals for the impact of DPP-4 496 
inhibitors on plasma adiponectin concentrations. Lower plot shows leave-one-out sensitivity analysis. 497 
Figure 3. Forest plot displaying weighted mean difference and 95% confidence intervals for the impact of DPP-4 498 
inhibitors on plasma adiponectin concentrations in trials with vildagliptin (A), trials with sitagliptin (B), trials lasting < 499 
48 weeks (C), trials lasting ≥ 48 weeks (D), placebo-controlled trials (E) and active-controlled trials (F).  500 
Figure 4. Meta-regression plots of the association between mean changes in plasma adiponectin concentrations and 501 
duration of treatment with DPP-4 inhibitors. The size of each circle is inversely proportional to the variance of change. 502 
Figure 5. Funnel plot detailing publication bias in the studies reporting the impact of DPP-4 inhibitors on plasma 503 
adiponectin concentrations. Open diamond represents observed effect size; closed diamond represents imputed effect 504 
size. 505 
 506 
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Table 1. Demographic characteristics of the included studies.  
Study  Derosa8, 2010 
 
Derosa10, 2012 
 
Derosa9, 2012 
 
Forst13, 2013 
 
Hibuse25, 2014 
 
Shimoda15,2014 
 
Derosa14, 2014 
 
Mikada30, 
2014 
 
Location  Italy  Italy Italy Germany Japan  Japan Italy Japan  
Design  Randomized 
double-blind trial 
 
Randomized 
double-blind 
placebo-
controlled trial  
 
Randomized 
double-blind 
placebo-
controlled trial  
 
Randomized 
open-label trial  
 
Randomized controlled trial 
 
Randomized open-
label trial  
 
Randomized 
double-blind 
controlled trial  
 
Randomized 
open-label  trial  
 
Duration  12 months 
 
12 months 12 months 24 weeks  3 months  12 weeks 6 months 24 weeks 
Inclusion criteria  Poorly controlled 
T2DM patients 
 
Poorly controlled 
T2DM patients 
 
Poorly controlled 
T2DM patients 
 
T2DM patients 
 
Poorly controlled T2DM 
patients 
 
T2DM patients 
 
Poorly 
controlled 
T2DM patients 
 
Overweight 
T2DM patients 
 
Intervention  Treatment 
pioglitazone + 
sitagliptin 100 
mg 
Controls 
pioglitazone + 
metformin 
 
Treatment 
metformin+ 
sitagliptin 100 mg 
Controls 
metformin+ 
placebo 
Treatment 
metformin+ 
vildagliptin 
100mg 
Controls 
metformin+ 
placebo 
Treatment 
metformin+ 
vildagliptin 
100mg  
Controls 
metformin+ 
glimepiride 
Treatment sitagliptin 25/100 
mg ± 
biguanides/sulfonylureas 
Controls biguanides and/or 
sulfonylureas 
Treatment 
sitagliptin 50/100 
mg 
Controls 
glimepiride 
Treatment 
metformin+ 
vildagliptin 100 
mg 
Controls 
metformin+ 
glimepiride 
Arm 1°  
Sitagliptin 50 
mg 
Arm 2* 
Sitagliptin 50 
mg+miglitol 
Controls# 
miglitol 
Participants  Treatment 75 
Controls 76 
 
Treatment 91 
Controls 87 
 
Treatment 84 
Controls 83 
 
Treatment 22 
Controls 22 
Treatment 16 
Controls 10 
Treatment 25 
Controls 25 
Treatment 83 
Controls 70 
 
Arm 1 14 
Arm 2 13 
Controls 14 
Age (years) Treatment 57±5 
Controls 58±6 
Treatment 56±9 
Controls 55±8  
Treatment 54±8 
Controls 52±7 
NS 
 
Treatment 63 (2) 
Controls 56 (5) 
Treatment 64±10 
Controls 62±14 
Treatment 60±10 
Controls 57±9 
Arm 1 59±12 
Arm 2 61±12 
17 
 
      Controls 59±7 
Gender (M/F)  Treatment 37/38 
Controls 39/37 
 
Treatment 42/49  
Controls 44/43 
Treatment 42/42 
Controls 43/40 
 
NS Treatment 9/7  
Controls 6/4  
 
Treatment 16/9 
Controls 15/10  
 
Treatment 42/44  
Controls 36/34 
 
Arm 1 11/3 
Arm 2 7/6 
Controls 11/3 
BMI (kg/m2) Treatment 
27.9±1.5 
Controls 
27.7±1.3 
 
Treatment 
28.1±1.2 
Controls 28.9±2.0 
 
Treatment 
27.9±1.5 
Controls 27.8±1.4 
 
NS Treatment 24.9 (1.2) 
Controls 28.1 (1.4) 
 
Treatment 
24.9±4.1 
Controls 25.3±3.6 
 
Treatment 
27.9±1.6 
Controls 
27.7±1.3  
 
Arm 1 28.8±2.5 
Arm 2 28.3±2.5 
Controls 
29.5±5.5 
Smokers (%) Treatment 36 
Controls 39 
Treatment 24 
Controls 26 
Treatment 23 
Controls 25  
 
NS NS 
 
NS Treatment 30 
Controls 30 
 
NS  
Glucose (mg/dL)  Treatment 
143±19 
Controls 142±18 
Treatment 
143±16 
Controls 141±13 
 
Treatment 
141±15 
Controls 139±14 
Treatment 
151±27 
Controls 
148±34 
 
Treatment 142 (6) 
Controls 156 (10) 
Treatment 142±32 
Controls 145±33 
 
Treatment 
140±18 
Controls 139±16  
 
Arm 1 135±23 
Arm 2 144±29 
Controls 
133±22 
 
Insulin (μU/mL) Treatment 
18.4±3.6 
Controls 
18.2±3.4 
Treatment 
18.1±4.2 
Controls 18.4±4.5 
Treatment 
17.9±4.2 
Controls 17.3±3.9 
Treatment 
12.9±6.7 
Controls 
12.9±7.2 
NS Treatment 8.0±4.6 
Controls 8.3±5.0 
Treatment 
19.1±4.4  
Controls 
18.3±3.8 
 
Arm 1 9.5±4.7 
Arm 2 9.5±11.0 
Controls 
7.0±5.4 
HOMA-IR 
(mmol/L×μU/mL) 
Treatment 
6.7±2.5 
Controls 6.4±2.3 
 
Treatment 
6.4±2.3 
Controls 6.4±2.2 
 
Treatment 
6.3±2.1 
Controls 6.0±2.0 
 
NS Treatment 2.0 (0.3) 
Controls 5.0 (2.1)  
 
NS 
 
Treatment 
6.6±2.4  
Controls 6.3±2.2 
 
NS 
 
HOMA-β 
(µU×mL-1/mmol×L-
1) 
Treatment 
54.6±49.9  
Controls 
Treatment 
80.3±65.7 
Controls 
Treatment 
81.9±65.1  
Controls 
NS Treatment 29.7 (5.7) 
Controls 45.6 (12.1)  
 
NS NS 
 
NS 
 
18 
 
 52.1±47.8   
 
83.7±69.3 
 
80.8±64.2   
 
HbA1c (%) Treatment 
8.5±0.9  
Controls 8.4±0.8   
 
Treatment 
8.1±0.8 
Controls 8.0±0.7 
 
Treatment 
8.1±0.6  
Controls 8.2±0.7   
 
Treatment 
7.4±0.7 
Controls 
7.3±0.6 
Treatment 7.5 (0.2) 
Controls 7.8 (0.4) 
 
 
Treatment 7.3±0.5 
Controls 7.5±0.6 
 
Treatment 
7.9±0.9 
Controls 7.8±0.8 
Arm 1 7.5±0.9 
Arm 2 7.1±0.8 
Controls 
6.9±0.5 
Total cholesterol 
(mg/dL) 
NS NS NS NS NS   
 
Treatment 185±29 
Controls 178±23 
Treatment 
194±23 
Controls 189±19 
 
NS 
HDL-cholesterol 
(mg/dL) 
NS NS NS NS Treatment 58 (2) 
Controls 51 (4) 
 
Treatment 55±15 
Controls 47±10 
 
Treatment 43±8 
Controls 39±4 
 
Arm 1 50±13 
Arm 2 55±10 
Controls 54±16 
LDL- cholesterol 
(mg/dL) 
NS NS NS NS Treatment 119 (7) 
Controls 130 (12)   
 
Treatment 104±27 
Controls 99±18 
 
Treatment 
139±15 
Controls 139±15 
 
Arm 1 125±22 
Arm 2 133±24 
Controls 
123±22 
Triglycerides 
(mg/dL) 
NS NS NS NS Treatment 157 (26) 
Controls 228 (39)   
 
Treatment 133±71 
Controls 157±68 
 
Treatment 
133±44 
Controls 142±53 
 
Arm 1 227±135 
Arm 2 190±172 
Controls 
180±110 
Hs-CRP (mg/L) 
 
Treatment 
2.1±1.0 
Controls 2.0±0.9 
Treatment 
1.8±0.7 
Controls 2.0±0.9 
 
Treatment 
1.9±2.0 
Controls 1.7±0.8 
NS NS NS Treatment 
2.2±1.3 
Controls 2.2±1.3 
 
NS 
Adiponectin 
(μg/mL) 
Treatment 
5.4±0.9  
Controls 5.3±0.8   
 
Treatment 
5.0±0.8  
Controls 5.2±1.1 
 
Treatment 
5.2±1.0  
Controls 5.4±1.2   
 
Treatment 
5.0±3.5 
Controls 
5.6±3.1 
Treatment 6.7±0.8 
Controls 4.6±0.3   
 
Treatment 7.0±3.6 
Controls 7.6±3.5 
 
Treatment 
4.8±1.6  
Controls 4.5±1.3 
 
Arm 1 6.5±3 
Arm 2 7.5±4 
Controls 
7.4±2.3 
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° Arm1: 50 mg of sitagliptin once a day; *Arm 2: 50 mg of sitagliptin once a day+50 mg of miglitol three times a day; # Controls: 50 mg of sitagliptin once a day 
Data are expressed as mean ± SD or mean (SEM)   
Abbreviations: BMI = body mass index; HOMA-IR = homeostasis model assessment – insulin resistance; HbA1c= glycosylated hemoglobin;  Hs-CRP = high sensitive C 
reactive protein; NS = non stated; T2DM = type 2 diabetes mellitus 
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Table 2. Risk of bias assessment in the studies included in this meta-analysis.  
Study Random 
sequence 
generation 
Allocation 
concealment 
Blinding Incomplete 
outcome data 
Selective 
reporting 
Free of 
other bias 
Derosa8, 2010 L L L L L L 
Derosa9, 2012 L L L L L L 
Derosa10, 2012 L L L L L L 
Forst13, 2013 U U H U L L 
Derosa14, 2014 L L L L L L 
Shimoda15, 2014 L H H L L L 
Hibuse25, 2014 U U H L L H 
Mikada30, 2014 U U H L L H 
 
 
Criteria defined for quality assessment are based on the Cochrane guidelines. 
Abbreviations: H, high risk of bias; L low risk of bias; U unclear or unrevealed risk of bias 
 
